Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy.

about

Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy.

Item

http://www.wikidata.org/entity/Q49335307

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Single oral dose acute and sub ...... itor combination drug therapy.

@en

Single oral dose acute and sub ...... itor combination drug therapy.

@nl

type

Item

label

Single oral dose acute and sub ...... itor combination drug therapy.

@en

Single oral dose acute and sub ...... itor combination drug therapy.

@nl

prefLabel

Single oral dose acute and sub ...... itor combination drug therapy.

@en

Single oral dose acute and sub ...... itor combination drug therapy.

@nl

P1476

Single oral dose acute and sub ...... itor combination drug therapy.

@en

P2093

Brian Smith

http://www.w3.org/2001/XMLSchema#string

Mien-Chie Hung

http://www.w3.org/2001/XMLSchema#string

Mihai Gagea

http://www.w3.org/2001/XMLSchema#string

Rene Flores

http://www.w3.org/2001/XMLSchema#string

Suzanne Craig

http://www.w3.org/2001/XMLSchema#string

Yi-Hsin Hsu

http://www.w3.org/2001/XMLSchema#string

P2860

Crizotinib: A comprehensive review

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer

The status of high-dose chemotherapy in breast cancer.

Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer

FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.

Mechanisms of drug resistance in cancer chemotherapy.

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.

Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.

P304

183-191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29416931

http://www.w3.org/2001/XMLSchema#string

P932

5794732

http://www.w3.org/2001/XMLSchema#string